Abstract
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
| Original language | English (US) |
|---|---|
| Article number | e1378156 |
| Journal | Molecular and Cellular Oncology |
| Volume | 4 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- FLT3
- acute myeloid leukemia
- chemotherapy
- hematopoietic progenitors
- myelosuppression
- quizartinib
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research
Fingerprint
Dive into the research topics of 'Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS